300406 九强生物
已收盘 07-22 15:00:00
资讯
新帖
简况
九强生物(300406.SZ)耗资7897.38万元完成回购0.82%股份
智通财经 · 07-22 19:58
九强生物(300406.SZ)耗资7897.38万元完成回购0.82%股份
九强生物获得发明专利授权:“丙戊酸衍生物在免疫检测中的用途”
证券之星 · 07-18
九强生物获得发明专利授权:“丙戊酸衍生物在免疫检测中的用途”
九强生物(300406)109.87万股限售股将于7月12日解禁,占总股本0.19%
证券之星 · 07-12
九强生物(300406)109.87万股限售股将于7月12日解禁,占总股本0.19%
九强生物(300406.SZ)累计回购309.5万股 耗资5264.68万元
智通财经 · 07-01
九强生物(300406.SZ)累计回购309.5万股 耗资5264.68万元
九强生物(300406)6月27日主力资金净卖出771.68万元
证券之星 · 06-28
九强生物(300406)6月27日主力资金净卖出771.68万元
九强生物(300406)6月26日主力资金净卖出322.62万元
证券之星 · 06-27
九强生物(300406)6月26日主力资金净卖出322.62万元
九强生物(300406.SZ)获13项医疗器械注册证
智通财经 · 06-26
九强生物(300406.SZ)获13项医疗器械注册证
九强生物涨8.18%,中泰证券一个月前给出“买入”评级
证券之星 · 06-26
九强生物涨8.18%,中泰证券一个月前给出“买入”评级
体外诊断概念盘中拉升,九强生物涨6.77%
自选股智能写手 · 06-26
体外诊断概念盘中拉升,九强生物涨6.77%
九强生物最新公告:中国医药投资拟不少于3000万元增持公司股份
证券之星 · 06-25
九强生物最新公告:中国医药投资拟不少于3000万元增持公司股份
九强生物(300406.SZ)股东中国医药投资拟斥不少于3000万元增持股份
智通财经 · 06-25
九强生物(300406.SZ)股东中国医药投资拟斥不少于3000万元增持股份
6月14日九强生物创60日新低,农银医疗保健股票基金重仓该股
证券之星 · 06-14
6月14日九强生物创60日新低,农银医疗保健股票基金重仓该股
九强生物最新公告:近日收到国家知识产权局颁发的1项专利证书
证券之星 · 06-07
九强生物最新公告:近日收到国家知识产权局颁发的1项专利证书
九强生物:获得两项发明专利证书 有利于提升公司核心竞争力
中国财富通 · 05-28
九强生物:获得两项发明专利证书 有利于提升公司核心竞争力
中泰证券:给予九强生物买入评级
证券之星 · 05-06
中泰证券:给予九强生物买入评级
九强生物新注册《MDC7500全自动凝血分析仪操作软件V1.1.2.000051》项目的软件著作权
证券之星 · 04-30
九强生物新注册《MDC7500全自动凝血分析仪操作软件V1.1.2.000051》项目的软件著作权
九强生物最新公告:一季度净利润1.21亿元 同比增长8.67%
证券之星 · 04-28
九强生物最新公告:一季度净利润1.21亿元 同比增长8.67%
图解九强生物一季报:第一季度单季净利润同比增8.67%
证券之星 · 04-28
图解九强生物一季报:第一季度单季净利润同比增8.67%
九强生物(300406.SZ)发布一季度业绩,净利润1.21亿元,增长8.67%
智通财经 · 04-28
九强生物(300406.SZ)发布一季度业绩,净利润1.21亿元,增长8.67%
九强生物新注册《Gi1600全自动化学发光免疫分析仪操作软件V1.2.0》项目的软件著作权
证券之星 · 04-27
九强生物新注册《Gi1600全自动化学发光免疫分析仪操作软件V1.2.0》项目的软件著作权
暂无数据
公司概况
公司名称:
北京九强生物技术股份有限公司
所属行业:
医药制造业
上市日期:
2014-10-30
主营业务:
北京九强生物技术股份有限公司主营业务是生化诊断、血凝检测、血型检测和肿瘤病理诊断的研发、生产和销售。主要产品包括胱抑素C、同型半胱氨酸、胆汁酸(TBA)、载脂蛋白A1、载脂蛋白B、小而密低密度脂蛋白胆固醇、肌酸激酶同工酶(mass法)等生化诊断试剂。2023年2月22日,2022年(第29批)新认定国家企业技术中心名单及全部国家企业技术中心名单公布,公司成功入选,荣获“国家企业技术中心”认定。
发行价格:
14.32
{"stockData":{"symbol":"300406","market":"SZ","secType":"STK","nameCN":"九强生物","latestPrice":14.17,"timestamp":1721631804000,"preClose":14.3,"halted":0,"volume":3615500,"delay":0,"floatShares":423000000,"shares":588000000,"eps":0.9065,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.13,"latestTime":"07-22 15:00:00","open":14.3,"high":14.39,"low":14.08,"amount":51426600,"amplitude":0.0217,"askPrice":14.18,"askSize":230,"bidPrice":14.17,"bidSize":57,"shortable":0,"etf":0,"ttmEps":0.9065,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721698200000},"adr":0,"adjPreClose":14.3,"symbolType":"stock","openAndCloseTimeList":[[1721611800000,1721619000000],[1721624400000,1721631600000]],"highLimit":15.73,"lowLimit":12.87,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":588446310,"pbRate":2.29,"roa":"--","roe":"3.19%","epsLYR":0.9,"committee":0.137139,"marketValue":8338000000,"floatMarketCap":5998000000,"peRate":15.63155,"changeRate":-0.0091,"turnoverRate":0.0085,"status":1},"requestUrl":"/m/hq/s/300406/tweets","defaultTab":"tweets","newsList":[{"id":"2453769258","title":"九强生物(300406.SZ)耗资7897.38万元完成回购0.82%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2453769258","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453769258?lang=zh_cn&edition=full","pubTime":"2024-07-22 19:58","pubTimestamp":1721649480,"startTime":"0","endTime":"0","summary":"智通财经APP讯,九强生物(300406.SZ)发布公告,截至2024年7月19日,公司本次回购股份的实施期限届满,公司累计通过股份回购专用账户以集中竞价方式实施回购公司股份482.51万股,占公司总股本的0.82%,最高成交价为19.00元/股,最低成交价为14.07元/股,支付的总金额为7897.38万元(不含交易费用)。至此,公司本次回购股份方案已实施完毕。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1154107.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300406","BK0239","BK0077","BK0046","BK0012","BK0028"],"gpt_icon":0},{"id":"2452681195","title":"九强生物获得发明专利授权:“丙戊酸衍生物在免疫检测中的用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2452681195","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452681195?lang=zh_cn&edition=full","pubTime":"2024-07-18 02:25","pubTimestamp":1721240701,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示九强生物新获得一项发明专利授权,专利名为“丙戊酸衍生物在免疫检测中的用途”,专利申请号为CN202211396766.7,授权日为2024年7月16日。具体而言,本申请涉及一种丙戊酸衍生物及其制备方法,以及与含有上述丙戊酸衍生物的试剂盒及其配制方法。本申请的丙戊酸检测试剂盒简便、快捷、成本低,可以在多种主流机型上进行自动化检测。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071800002367.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300406","BK0077","BK0028","BK0012"],"gpt_icon":0},{"id":"2450334339","title":"九强生物(300406)109.87万股限售股将于7月12日解禁,占总股本0.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450334339","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450334339?lang=zh_cn&edition=full","pubTime":"2024-07-12 08:02","pubTimestamp":1720742532,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息整理,九强生物于7月12日将有109.87万股限售股份解禁,为公司股权激励限售股份,占公司总股本0.19%。最近一年内,该股累计解禁8720.93万股,占总股本的14.82%。本次解禁后,公司还有1.65亿股限售股份,占总股本28.07%。九强生物主营业务:生化诊断、血凝检测、血型检测和肿瘤病理检测的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071200012236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0239","300406","BK0077","BK0028","BK0046"],"gpt_icon":0},{"id":"2448280965","title":"九强生物(300406.SZ)累计回购309.5万股 耗资5264.68万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448280965","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448280965?lang=zh_cn&edition=full","pubTime":"2024-07-01 16:38","pubTimestamp":1719823122,"startTime":"0","endTime":"0","summary":"智通财经APP讯,九强生物(300406.SZ)公告,公司截至2024年6月30日以集中竞价交易方式实施回购股份合计309.5万股,占公司目前总股本的0.5260%,成交总金额为人民币5264.68万元(不含交易费用)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1143560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","BK0046","BK0239","BK0028","BK0012","300406"],"gpt_icon":0},{"id":"2446169375","title":"九强生物(300406)6月27日主力资金净卖出771.68万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446169375","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446169375?lang=zh_cn&edition=full","pubTime":"2024-06-28 09:20","pubTimestamp":1719537651,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月27日收盘,九强生物报收于15.45元,下跌4.22%,换手率1.7%,成交量7.16万手,成交额1.12亿元。6月27日的资金流向数据方面,主力资金净流出771.68万元,占总成交额6.92%,游资资金净流入1346.17万元,占总成交额12.07%,散户资金净流出574.5万元,占总成交额5.15%。九强生物主营业务:生化诊断、血凝检测、血型检测和肿瘤病理检测的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062800015770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0239","300406","BK0077","BK0028","BK0046"],"gpt_icon":0},{"id":"2446732900","title":"九强生物(300406)6月26日主力资金净卖出322.62万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446732900","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446732900?lang=zh_cn&edition=full","pubTime":"2024-06-27 09:12","pubTimestamp":1719450758,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月26日收盘,九强生物报收于16.13元,上涨8.18%,换手率2.75%,成交量11.61万手,成交额1.82亿元。6月26日的资金流向数据方面,主力资金净流出322.62万元,占总成交额1.77%,游资资金净流入1239.63万元,占总成交额6.81%,散户资金净流出917.01万元,占总成交额5.04%。融券方面,融券卖出37.29万股,融券偿还8.31万股,融券余量78.89万股,融券余额1272.46万元。九强生物主营业务:生化诊断、血凝检测、血型检测和肿瘤病理检测的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062700013423.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300406","BK0239","BK0046","BK0028","BK0012","BK0077"],"gpt_icon":0},{"id":"2446356392","title":"九强生物(300406.SZ)获13项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2446356392","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446356392?lang=zh_cn&edition=full","pubTime":"2024-06-26 16:27","pubTimestamp":1719390427,"startTime":"0","endTime":"0","summary":"智通财经APP讯,九强生物(300406.SZ)发布公告,2024年6月26日,公司收到北京市药品监督管理局颁发的《医疗器械注册证》,共计13项。取得医疗器械注册证有利于增强公司的核心竞争力,对公司未来发展具有正面影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140750.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300406","BK0239","09996","BK1574","BK0077","BK0046","BK1583","BK1100","159883","09997","BK0012","BK0028","BK1222"],"gpt_icon":0},{"id":"2446655356","title":"九强生物涨8.18%,中泰证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2446655356","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446655356?lang=zh_cn&edition=full","pubTime":"2024-06-26 16:26","pubTimestamp":1719390418,"startTime":"0","endTime":"0","summary":"今日九强生物涨8.18%,收盘报16.13元。2024年5月6日,中泰证券研究员祝嘉琦,谢木青,于佳喜发布了对九强生物的研报《政策影响下业绩稳健,持续看好病理业务+国改赋能》,该研报对九强生物给出“买入”评级。公司当前股价对应2024-2026年约18、15、11倍PE,考虑公司生化、血凝业务趋势向上,病理赛道持续高景气,化学发光等新产品有望快速放量,维持“买入”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062600031779.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300406","600918"],"gpt_icon":0},{"id":"2446433318","title":"体外诊断概念盘中拉升,九强生物涨6.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2446433318","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446433318?lang=zh_cn&edition=full","pubTime":"2024-06-26 13:13","pubTimestamp":1719378827,"startTime":"0","endTime":"0","summary":"06月26日,体外诊断概念盘中拉升,截至13点13分,体外诊断概念整体指数上涨2.05%,报822.710点。从个股上来看,该概念的成分股中,九强生物涨6.77%,金域医学涨幅超过5%。从资金上来看,截止发稿,体外诊断概念概念主力净流入为-3790.18万,其中金域医学受到资金热捧,主力净流入2635.99万;拉长时间线来看,该板块近20日主力资金净流入-21.84亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240626131347941f1339&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240626131347941f1339&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0236","BK0046","BK0028","BK0239","SG9999001069.SGD","BK0042","BK0012","603882","BK0077","BK0284","300406"],"gpt_icon":0},{"id":"2446846091","title":"九强生物最新公告:中国医药投资拟不少于3000万元增持公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2446846091","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446846091?lang=zh_cn&edition=full","pubTime":"2024-06-25 21:19","pubTimestamp":1719321559,"startTime":"0","endTime":"0","summary":"九强生物公告,公司持股5%以上的股东中国医药投资有限公司计划自6月25日至12月24日,通过集中竞价交易、大宗交易等方式增持公司股票,计划增持金额不少于3000万元(含6月25日已增持部分)。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062500041750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","BK0028","BK0175","BK0188","BK0010","BK0185","BK0012","BK0239","300406","BK0082","BK0077","BK0046","600056"],"gpt_icon":0},{"id":"2446845843","title":"九强生物(300406.SZ)股东中国医药投资拟斥不少于3000万元增持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2446845843","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446845843?lang=zh_cn&edition=full","pubTime":"2024-06-25 21:03","pubTimestamp":1719320597,"startTime":"0","endTime":"0","summary":"智通财经APP讯,九强生物(300406.SZ)发布公告,公司持股5%以上的股东中国医药投资有限公司计划自2024年6月25日至2024年12月24日,通过集中竞价交易、大宗交易等法律法规允许的方式增持公司股票,计划增持公司股份金额不少于3000万元(含)人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140416.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0250","BK0188","BK0185","BK0175","BK0010","600056","BK0077","BK0012","BK0028","BK0082","300406","BK0046","BK0239"],"gpt_icon":0},{"id":"2443648518","title":"6月14日九强生物创60日新低,农银医疗保健股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2443648518","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443648518?lang=zh_cn&edition=full","pubTime":"2024-06-14 16:16","pubTimestamp":1718353010,"startTime":"0","endTime":"0","summary":"证券之星消息,6月14日九强生物创60日新低,收盘报16.45元,当日跌3.86%,换手率2.88%,成交量12.16万手,成交额2.03亿元。重仓九强生物的前十大公募基金请见下表:该股最近90天内共有3家机构给出评级,买入评级3家。根据2024基金Q1季报公募基金重仓股数据,重仓该股的公募基金共17家,其中持有数量最多的公募基金为农银医疗保健股票。该公募基金现任基金经理为梦圆。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061400029160.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0012","BK0028","300406","BK0046","BK0239"],"gpt_icon":0},{"id":"2441031757","title":"九强生物最新公告:近日收到国家知识产权局颁发的1项专利证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2441031757","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441031757?lang=zh_cn&edition=full","pubTime":"2024-06-07 16:32","pubTimestamp":1717749156,"startTime":"0","endTime":"0","summary":"九强生物公告,公司于近期收到国家知识产权局颁发的1项专利证书,专利名称为妥布霉素检测试剂盒。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060700030445.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0077","BK0012","300406","BK0046"],"gpt_icon":0},{"id":"2438534768","title":"九强生物:获得两项发明专利证书 有利于提升公司核心竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2438534768","media":"中国财富通","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438534768?lang=zh_cn&edition=full","pubTime":"2024-05-28 17:08","pubTimestamp":1716887287,"startTime":"0","endTime":"0","summary":"中国财富通5月28日 - 九强生物(300406)公告称,公司于近期收到国家知识产权局颁发的2项专利证书,专利名称分别为甘胆酸检测试剂盒、前列腺酸性磷酸酶的定量检测试剂盒。上述发明专利证书的取得有利于发挥公司的知识产权优势,促进技术创新,有利于提升公司的核心竞争力,有利于公司形成持续创新机制。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=foGmc6A0aGM%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","BK0239","300406","BK0046","BK0028","BK0077"],"gpt_icon":0},{"id":"2433546012","title":"中泰证券:给予九强生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2433546012","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433546012?lang=zh_cn&edition=full","pubTime":"2024-05-06 10:45","pubTimestamp":1714963559,"startTime":"0","endTime":"0","summary":"中泰证券股份有限公司谢木青,祝嘉琦,于佳喜近期对九强生物进行研究并发布了研究报告《政策影响下业绩稳健,持续看好病理业务+国改赋能》,本报告对九强生物给出买入评级,当前股价为18.95元。公司当前股价对应2024-2026年约18、15、11倍PE,考虑公司生化、血凝业务趋势向上,病理赛道持续高景气,化学发光等新产品有望快速放量,维持“买入”评级。最新盈利预测明细如下:该股最近90天内共有3家机构给出评级,买入评级3家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050600005710.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600918","300406"],"gpt_icon":0},{"id":"2431168868","title":"九强生物新注册《MDC7500全自动凝血分析仪操作软件V1.1.2.000051》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2431168868","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431168868?lang=zh_cn&edition=full","pubTime":"2024-04-30 01:10","pubTimestamp":1714410625,"startTime":"0","endTime":"0","summary":"证券之星消息,近日九强生物(300406)新注册了《MDC7500全自动凝血分析仪操作软件V1.1.2.000051》项目的软件著作权。今年以来九强生物新注册软件著作权2个。结合公司2023年年报财务数据,2023年公司在研发方面投入了1.63亿元,同比增18.73%。数据来源:企查查以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000001035.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0012","BK0028","300406","BK0046","BK0239"],"gpt_icon":0},{"id":"2430051773","title":"九强生物最新公告:一季度净利润1.21亿元 同比增长8.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430051773","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430051773?lang=zh_cn&edition=full","pubTime":"2024-04-28 20:30","pubTimestamp":1714307457,"startTime":"0","endTime":"0","summary":"九强生物发布2024年一季度报告,报告期内实现营业收入3.94亿元,同比增长5.49%。归属于上市公司股东的净利润1.21亿元,同比增长8.67%。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042800009103.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300406"],"gpt_icon":0},{"id":"2430031088","title":"图解九强生物一季报:第一季度单季净利润同比增8.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430031088","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430031088?lang=zh_cn&edition=full","pubTime":"2024-04-28 17:46","pubTimestamp":1714297602,"startTime":"0","endTime":"0","summary":"证券之星消息,九强生物2024年一季报显示,公司主营收入3.94亿元,同比上升5.49%;归母净利润1.21亿元,同比上升8.67%;扣非净利润1.21亿元,同比上升10.91%;负债率27.2%,投资收益111.52万元,财务费用1065.96万元,毛利率76.86%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042800006478.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300406"],"gpt_icon":0},{"id":"2430316500","title":"九强生物(300406.SZ)发布一季度业绩,净利润1.21亿元,增长8.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430316500","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430316500?lang=zh_cn&edition=full","pubTime":"2024-04-28 17:42","pubTimestamp":1714297350,"startTime":"0","endTime":"0","summary":"智通财经APP讯,九强生物(300406.SZ)发布2024年一季度报告,报告期内实现营业收入3.94亿元,同比增长5.49%。归属于上市公司股东的净利润1.21亿元,同比增长8.67%。归属于上市公司股东的扣除非经常性损益的净利润1.21亿元,同比增长10.91%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1113416.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300406"],"gpt_icon":0},{"id":"2430778984","title":"九强生物新注册《Gi1600全自动化学发光免疫分析仪操作软件V1.2.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2430778984","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430778984?lang=zh_cn&edition=full","pubTime":"2024-04-27 01:25","pubTimestamp":1714152348,"startTime":"0","endTime":"0","summary":"证券之星消息,近日九强生物(300406)新注册了《Gi1600全自动化学发光免疫分析仪操作软件V1.2.0》项目的软件著作权。今年以来九强生物新注册软件著作权1个。结合公司2023年年报财务数据,2023年公司在研发方面投入了1.63亿元,同比增18.73%。数据来源:企查查以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042700002419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0012","BK0028","300406","BK0046","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2014-10-30","address":"北京市海淀区花园东路15号旷怡大厦5层","stockEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":-0.0503},{"period":"3month","weight":-0.1722},{"period":"6month","weight":-0.2066},{"period":"1year","weight":-0.2997},{"period":"ytd","weight":-0.2502}],"companyName":"北京九强生物技术股份有限公司","boardCode":"AI0027","perCapita":"32092股","boardName":"医药制造业","registeredCapital":"58844万元","compareEarnings":[{"period":"1week","weight":-0.0033},{"period":"1month","weight":-0.0113},{"period":"3month","weight":-0.0191},{"period":"6month","weight":0.0509},{"period":"1year","weight":-0.0642},{"period":"ytd","weight":-0.0036}],"survey":" 北京九强生物技术股份有限公司主营业务是生化诊断、血凝检测、血型检测和肿瘤病理诊断的研发、生产和销售。主要产品包括胱抑素C、同型半胱氨酸、胆汁酸(TBA)、载脂蛋白A1、载脂蛋白B、小而密低密度脂蛋白胆固醇、肌酸激酶同工酶(mass法)等生化诊断试剂。2023年2月22日,2022年(第29批)新认定国家企业技术中心名单及全部国家企业技术中心名单公布,公司成功入选,荣获“国家企业技术中心”认定。","serverTime":1721677014650,"listedPrice":14.32,"stockholders":"13186人(较上一季度增加2.43%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"九强生物(300406)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供九强生物(300406)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"九强生物,300406,九强生物股票,九强生物股票老虎,九强生物股票老虎国际,九强生物行情,九强生物股票行情,九强生物股价,九强生物股市,九强生物股票价格,九强生物股票交易,九强生物股票购买,九强生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"九强生物(300406)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供九强生物(300406)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}